Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01675622
Other study ID # OXYC10-CN-303
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date January 2011
Est. completion date July 2012

Study information

Verified date April 2018
Source Mundipharma (China) Pharmaceutical Co. Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.


Description:

To compare the efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.


Recruitment information / eligibility

Status Completed
Enrollment 242
Est. completion date July 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Patients of either sex aged 18 to 80 years inclusive, who with cancers of all type.

2. Patients with moderate to severe cancer pain, whose pain intensity Numeric Rating Scale =4.

3. Patients who can understand and are able to complete Numeric Rating Scale and Brief Pain Inventory assessment.

4. Patients who have given written informed consent to participate in the study.

Exclusion Criteria:

1. Patients who are pregnant, or lactating.

2. Patients who are unable to manage their pain effectively with opioids.

3. Patient who need =120mg morphine or equivalent for treatment of pain at time of study entry;

4. Patients who are receiving chemotherapy, or still under the responsive period of chemotherapy (patients who are at the interval period of chemotherapy can be enrolled into study. That is to say, patients who completed chemotherapy for more than 2 weeks can enrolled, or patients has completed chemotherapy for at least one week could be enrolled at the discretion of the investigator).

5. Patients who have received radio-therapy for bony metastasis, patients receiving radiotherapy within the 4 week period before study entry (patient receiving radiotherapy for area other than pain area can be enrolled) , or patients who were scheduled to receive radiotherapy for pain area during study period.

6. Patients are receiving or should receive anti-convulsion drugs/anti- depression drugs considered by investigator for the treatment of neuropathy pain. Patients are receiving or should receive any analgesic other than study medicine, which including NSAIDs.

7. Patients with other unstable disease, or with dysfunction of important organ.

8. Patients with an ongoing infection, abscess or fever.

9. Patient with serious abnormal liver/ renal function (ALT/Aspartate Transaminase/creatinine/urea nitrogen) which is higher than 3 times of upper limit;

10. Paralytic or mechanical ileus;

11. Persistent asthma, chronic obstructive diseases, and cor pulmonary;

12. Intracranial neoplasms, and intracranial hypertension with central respiratory depression risk.

13. Monoamine oxidase inhibitors (MAOIs) or same type drugs have been administered in last 2 weeks;

14. Patients who are currently taking active treatment for epilepsy or arrhythmias.

15. Patients with known sensitivity or record of specific or allergic reaction to oxycodone or morphine.

16. Patients excluded by the contra-indications, adverse drug reaction (ADRs) and drug interactions of oxycodone or morphine as detailed in the data sheet, summary of product characteristics or investigator's brochure.

17. Patients with a history of drug or alcohol abuse.

18. Patients who participated in another clinical research study involving a new chemical entity within one month prior to study entry.

19. Patients whose concomitant medication is likely to be changed within the study period, with the exception of treatment for opioid side effects.

20. Patients who, in the opinion of the investigator, are unsuitable to participate in the study for any other reason not mentioned in the inclusion and exclusion criteria.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxycodone
dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
Morphine
Morphine tablets 10mg and 20mg, oral every 4-6 hours

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mundipharma (China) Pharmaceutical Co. Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Rating Scale (NRS) The numerical rating scale is the tool to assess pain level using a numerical rating scale. The primary outcome measurement is the average change of NRS score after double blind treatment between the two treatment groups. The NRS evaluates the pain level using number scale from 0 to 10. 0 means not painful and 10 means extremely painful. 1 to 3 is lightly pain, 4-6 is moderate pain and 7 to 10 is severe pain. There is no subscales used for NRS reporting. baseline up to 5-8 days (double blind period)
Secondary The Average Dose of Study Medicine Used During Double Blind Treatment Period the average dose of study medicine used during double blind treatment period between the two treatment groups. baseline up to 5-8 days (double blind period)
Secondary Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period The secondary outcome measurement is the change between BPI score at baseline and after completion of double blind treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in the passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items. baseline up to 5-8 days (double blind period)
Secondary Times of Breakthrough Pain Occurrence the times of breakthrough pain occurrence during double blind treatment phase between the two treatment groups Within 8 days after baseline
Secondary Patient Assessments of Satisfaction for Pain Management the number of patients of satisfaction for pain management between the two treatment groups at the end of double blind treatment and the open label treatment period. baseline up to 19-22 days (open label treatment)
Secondary Average Number of Titrations the average times to change the dose in order to find the proper dose between two treatment groups baseline up to 1-3 days(double blind period)
Secondary Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment The secondary outcome measurement is the change of BPI score from baseline to the end of open label treatment between the two treatment groups. The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. This tool measures the worst/least pain in passed 24 hours, and the average/current pain in last 24 hours. The scale is numerically from 0 to 10. 0 means not painful, 10 means extremely painful. The BPI is the average number of above 4 BPI Pain Items. baseline up to 19-22 days (open label treatment)
Secondary the Total Dose of Rescue Medicine for Breakthrough Pain. the total dose of rescue medicine for breakthrough pain during double blind phase between the two treatment groups baseline up to 22 days (double blind period)
Secondary Degree of Pain Relief Within 24hrs After Treatment Brief Pain Inventory (BPI) Change From Baseline to After Double Blind Period. The BPI is the average number of above 4 BPI Pain Items. For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%). baseline up to 5-8 days (double blind period)
Secondary Brief Pain Inventory (BPI) Change From Baseline to Open Label Treatment For the degree of pain relief within 24hrs after treatment, 0 means zero relief and 100 means completely relief with unit of percentage(%). baseline up to 19-22 days (open label treatment)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients